The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body. The study compares Japanese and Caucasian people who are normal weight, overweight or with obesity. The participants will either get NNC0174-0833 (a potential new medicine) or placebo (a "dummy" medicine similar to the study medicine but without active ingredients) - which treatment any participant gets is decided by chance. Participants will get 1 injection by a study nurse at the clinic. The injection will be with a needle in a skin fold in the participant's stomach area. The study will last for about 4 months, but duration of participation for any participant will last up to about 2 months. The participants will have 8 clinic visits with the study staff.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
66
Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
Participants will receive NNC0174-0833 matched placebo subcutaneously.
Novo Nordisk Investigational Site
Glendale, California, United States
AUC0-∞,AM833: the area under the NNC0174-0833 plasma concentration-time curve from time 0 to infinity after single dose
Measured in h\*nmol/L
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Cmax,AM833: the maximum concentration of NNC0174-0833 in plasma
Measured in nmol/L
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Number of treatment emergent adverse events (TEAEs)
Count of events
Time frame: From time of first dosing (Day 1) until completion of the post-treatment follow-up visit (Day 36)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.